Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Eisai to Divest Rights to 2 CNS Drugs to UK’s CNX in France, Algeria
April 4, 2024
- Sawai Closes Sale of US Business to Taiwan CDMO
April 4, 2024
- Sumitomo Offloads Entire Stake in Roivant as Earnings Tank
April 3, 2024
- Daiichi’s TROP2 ADC Accepted for US FDA Review in Breast Cancer
April 3, 2024
- Axcelead-Teijin Drug Discovery Joint Venture Now Up and Running
April 2, 2024
- MS Med Copaxone Transferred to Teva Takeda Pharma
April 2, 2024
- Takeda to Hand Over Nihon Pharma to Alinamin in July
April 2, 2024
- Cheplapharm to Take Over 5 Brands from Clinigen in Japan
April 2, 2024
- Aculys Pharma Poaches Takeda Veteran as New CEO
April 2, 2024
- New Ono Chief Eager to Go Solo in US, Europe; BTK Med 1st Shield against Opdivo Patent Cliff
April 1, 2024
- Ying Chen Named as President of Bayer Holding in Japan
April 1, 2024
- Asahi Kasei Grabs Japan Commercial Rights to Doptelet’s ITP Use
April 1, 2024
- 5 Otsuka Execs Reel in 100 Million-Plus Pay in 2023: Securities Filing
April 1, 2024
- Chugai Workforce Down 200 in 2023 after Voluntary Buyout: Securities Report
April 1, 2024
- “Puberulic Acid” in Beni-Koji Supplements; Kobayashi Wants to Keep Healthcare Biz
April 1, 2024
- Uber Eats Launches Delivery Service for Prescription Drugs in Japan
March 29, 2024
- Taiho Bags Label Update for Lonsurf Combo Use with Bevacizumab
March 29, 2024
- BIKEN Files Nasal Flu Vaccine in Japan
March 29, 2024
- Padcev/Keytruda Accepted for Chinese Review for 1st Line Bladder Cancer Use
March 29, 2024
- Sumitomo-Sponsored Trial for Parkinson’s Cell Therapy to Commence in US
March 29, 2024
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…